About this Journal Submit a Manuscript Table of Contents
Journal of Drug Delivery
Volume 2013 (2013), Article ID 898146, 12 pages
Review Article

Clinical Trials with Pegylated Liposomal Doxorubicin in the Treatment of Ovarian Cancer

Department of Urology and Gynecology, National Cancer Institute, 80131 Naples, Italy

Received 27 December 2012; Revised 29 January 2013; Accepted 29 January 2013

Academic Editor: Michele Caraglia

Copyright © 2013 Carmela Pisano et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Citations to this Article [14 citations]

The following is the list of published articles that have cited the current article.

  • Zhong-min Wang, Joseph X. Ho, John R. Ruble, John Rose, Florian Rüker, Melanie Ellenburg, Robert Murphy, James Click, Elizabeth Soistman, Leslie Wilkerson, and Daniel C. Carter, “Structural Studies of Several Clinically Important Oncology Drugs in Complex with Human Serum Albumin,” Biochimica et Biophysica Acta (BBA) - General Subjects, 2013. View at Publisher · View at Google Scholar
  • Jean-Louis Mestas, R. Andrew Fowler, Tove J. Evjen, Lucie Somaglino, Alexei Moussatov, Jacqueline Ngo, Sabrina Chesnais, Sibylla Rognvaldsson, Sigrid L. Fossheim, Esben A. Nilssen, and Cyril Lafon, “Therapeutic efficacy of the combination of doxorubicin-loaded liposomes with inertial cavitation generated by confocal ultrasound in AT2 Dunning rat tumour model,” Journal of Drug Targeting, vol. 22, no. 8, pp. 688–697, 2014. View at Publisher · View at Google Scholar
  • Sarika M. Kamble, Sameer N. Goyal, and Chandragouda R. Patil, “Multifunctional pentacyclic triterpenoids as adjuvants in cancer chemotherapy: a review,” RSC Advances, vol. 4, no. 63, pp. 33370, 2014. View at Publisher · View at Google Scholar
  • Hongye Ye, Anis Abdul Karim, and Xian Jun Loh, “Current Treatment Options and Drug Delivery Systems as Potential Therapeutic Agents for Ovarian Cancer: A Review,” Materials Science and Engineering: C, 2014. View at Publisher · View at Google Scholar
  • Filippos Koinis, Aristidis Polyzos, Athina Christopoulou, Zafeiris Zafeiriou, Christos Emmanouilidis, Elisavet Papadimitraki, Antonia Kalykaki, Kostas Kalbakis, George Samonis, and Vassilis Georgoulias, “Salvage chemotherapy with docetaxel and pegylated liposomal doxorubicin in pretreated patients with platinum- and taxane-sensitive ovarian cancer: a multicenter phase II trial of the Hellenic Oncology Research Group (HORG),” Cancer Chemotherapy and Pharmacology, 2014. View at Publisher · View at Google Scholar
  • Naike Casagrande, Marta Celegato, Cinzia Borghese, Maurizio Mongiat, Alfonso Colombatti, and Donatella Aldinucci, “Preclinical Activity of the Liposomal Cisplatin Lipoplatin in Ovarian Cancer,” Clinical Cancer Research, vol. 20, no. 21, pp. 5496–5506, 2014. View at Publisher · View at Google Scholar
  • Alex Rabinovich, Agnihotram V. Ramanakumar, Susie Lau, and Walter H. Gotlieb, “Prolonged pegylated liposomal doxorubicin treatment for recurrent pelvic cancers: a feasibility study,” Acta Obstetricia et Gynecologica Scandinavica, 2015. View at Publisher · View at Google Scholar
  • Arunkumar Pitchaimani, Raju Baskar, Vasantharaja Raguraman, Vijayaraghavan Sundarrajan, Preetham Kumar Balasubramanian, Jeganathan Kulandaivel, and Premkumar Kumpati, “Near infra-red laser mediated photothermal and antitumor efficacy of doxorubicin conjugated gold nanorods with reduced cardiotoxicity in swiss albino mice,” Nanomedicine: Nanotechnology, Biology and Medicine, 2015. View at Publisher · View at Google Scholar
  • Giuseppina Bozzuto, and Agnese Molinari, “Liposomes as nanomedical devices,” International Journal of Nanomedicine, vol. 10, pp. 975–999, 2015. View at Publisher · View at Google Scholar
  • Jyothi B. Nair, Manu M. Joseph, Saswat Mohapatra, M. Safeera, Surajit Ghosh, T. T. Sreelekha, and Kaustabh Kumar Maiti, “A Dual-Targeting Octaguanidine-Doxorubicin Conjugate Transporter for Inducing Caspase-Mediated Apoptosis on Folate-Expressing Cancer Cells,” ChemMedChem, 2016. View at Publisher · View at Google Scholar
  • Jose F. Ponte, Olga Ab, Leanne Lanieri, Jenny Lee, Jennifer Coccia, Laura M. Bartle, Marian Themeles, Yinghui Zhou, Jan Pinkas, and Rodrigo Ruiz-Soto, “Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha–Targeting Antibody-Drug Conjugate, Potentiates the Activity of Standard of Care Therapeutics in Ovarian Cancer Models,” Neoplasia, vol. 18, no. 12, pp. 775–784, 2016. View at Publisher · View at Google Scholar
  • Marcin P Komorowski, AJ Robert McGray, Agnieszka Kolakowska, Kevin Eng, Margaret Gil, Mateusz Opyrchal, Bogumila Litwinska, Michael J Nemeth, Kunle O Odunsi, and Danuta Kozbor, “Reprogramming antitumor immunity against chemoresistant ovarian cancer by a CXCR4 antagonist-armed viral oncotherapy,” Molecular Therapy — Oncolytics, vol. 3, pp. 16034, 2016. View at Publisher · View at Google Scholar
  • Zvi Yaari, Dana da Silva, Assaf Zinger, Evgeniya Goldman, Ashima Kajal, Rafi Tshuva, Efrat Barak, Nitsan Dahan, Dov Hershkovitz, Mor Goldfeder, Janna Shainsky Roitman, and Avi Schroeder, “Theranostic barcoded nanoparticles for personalized cancer medicine,” Nature Communications, vol. 7, pp. 13325, 2016. View at Publisher · View at Google Scholar
  • Stefan Nikolić, Loganathan Rangasamy, Nevenka Gligorijević, Sandra Aranđelović, Siniša Radulović, Gilles Gasser, and Sanja Grgurić-Šipka, “Synthesis, characterization and biological evaluation of novel Ru(II)–arene complexes containing intercalating ligands,” Journal of Inorganic Biochemistry, 2016. View at Publisher · View at Google Scholar